Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement.
Oncologist
; 22(4): 480-483, 2017 04.
Article
in En
| MEDLINE
| ID: mdl-28242791
ABSTRACT
This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation. The Oncologist 2017;22480-483.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Down Syndrome
/
Cell Cycle Proteins
/
Receptor, Fibroblast Growth Factor, Type 1
/
Leukemoid Reaction
/
Neoplasms
Limits:
Female
/
Humans
/
Middle aged
Language:
En
Year:
2017
Type:
Article